Autoimmune hemolytic anemia: From lab to bedside

Area of Science:

• Immunohematology
• Transfusion Medicine
• Clinical Immunology

Background:

• Autoimmune hemolytic anemia (AIHA) is a significant clinical condition requiring specialized immunohematological and transfusion support.
• Identifying underlying disorders, such as lymphoproliferative or connective tissue diseases, is crucial for comprehensive AIHA patient care.
• The direct antiglobulin test (DAT) remains a cornerstone for diagnosing AIHA, despite advancements in transfusion medicine.

Purpose of the Study:

• To highlight the diagnostic significance of the direct antiglobulin test (DAT) in autoimmune hemolytic anemia (AIHA).
• To emphasize the role of sensitive gel technology in serologically diagnosing AIHA and characterizing red blood cell-bound autoantibodies.
• To discuss the challenges and strategies for transfusing AIHA patients, including the importance of antibody characterization and specialized testing.

Main Methods:

• Utilizing sensitive gel technology for rapid and simplified serological diagnosis of AIHA.
• Characterizing red blood cell-bound autoantibodies, including their class, subclass, and titer.
• Employing specialized serological tests like alloadsorption and autoadsorption for cross-matching challenges in AIHA patients.

Main Results:

• Sensitive gel technology facilitates accurate diagnosis and detailed characterization of autoantibodies in AIHA.
• A correlation exists between the strength of DAT, autoantibody characteristics (class, subclass, titer), and in vivo hemolysis.
• Specialized techniques like elution and adsorption can enhance blood safety in AIHA transfusions.

Conclusions:

• The direct antiglobulin test (DAT) is essential for AIHA diagnosis, with gel technology improving antibody characterization.
• Transfusing AIHA patients presents challenges, necessitating specialized techniques for ABO grouping and cross-matching.
• Providing "best match" or "least incompatible" units, alongside specialized testing, is vital for managing critical AIHA patients requiring transfusion.